ClinicalTrials.gg
Sign In
Not yet recruitingNCT07873853LLLT- piezoUpdated Oct 14, 2026

Impact of Various Acceleration Techniques on En-masse Retraction of Maxillary Anterior Teeth

An interventional study of low level LAZER therapy. and Retraction of Maxillary Anterior Teeth (en-mass) with conventional methods. in Accelerate Tooth Movement, sponsored by Al-Azhar University. Not yet recruiting at 1 site in Egypt. Open to participants aged 14 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

Updated Oct 14, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
14 Years to 25 Years
Sex
All
01

Study summary

Impact of Various Acceleration Techniques on En-masse Retraction of Maxillary Anterior Teeth: A Digital Software Evaluation (Comparative Clinical Study)

Read the detailed description

This study will be conducted as a prospective, control, clinical trial, a convenience sampling technique was used for patient selection.

02

Conditions studied

  • Accelerate Tooth Movement
03

In context

Lead sponsor

Al-Azhar University is the lead sponsor of 525 studies on the registry; 171 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse Al-Azhar University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 14 to 25.
  2. Patients who need upper or all four first premolar extraction for canine retraction.
  3. No systemic disease.
  4. No previous extraction of permanent teeth.
  5. Not receiving medical treatment that could interfere with bone metabolism.
  6. A good level of oral hygiene.
  7. No periodontal disease or radiographic evidence of bone loss

Exclusion criteria

Exclusion Criteria:

1. Periodontally compromised patients. 2. Missing teeth. 3. Systemic diseases. 4. Drug dependencies. 5. Uncooperative patient.

-

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Retraction of Maxillary Anterior Teeth (en-mass) with conventional methods.

    Procedure: Retraction of Maxillary Anterior Teeth (en-mass) with conventional methods.

  • Experimental
    Retraction of Maxillary Anterior Teeth (en-mass) aided with low level LAZER therapy.

    Device: low level LAZER therapy.

  • Experimental
    Retraction of Maxillary Anterior Teeth (en-mass) aided with piezocision method.

    Procedure: Piezocision-assisted orthodontic retraction

Interventions

  • Devicelow level LAZER therapy.

    Application of low-level laser therapy (LLLT) as an adjunct to conventional en-masse retraction to accelerate tooth movement.

  • ProcedureRetraction of Maxillary Anterior Teeth (en-mass) with conventional methods.

    Standard en-masse retraction using conventional orthodontic mechanics without adjunctive acceleration techniques.

  • ProcedurePiezocision-assisted orthodontic retraction

    Minimally invasive surgical procedure (piezocision) used alongside conventional mechanics to facilitate accelerated tooth movement during en-masse retraction.

06

What researchers measure

Primary outcomes

  1. En-masse retraction of maxillary anterior teeth

    Time frame: Base line (T0), 1 month (T1), 2months (T2), and 3months(T3) after the start of retraction

07

Study locations

1 site
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07873853
Lead sponsor
Al-Azhar University
Responsible party
Alhassan Hatem Mohamed (principal investigator ,clinical researcher, ALAzhar university ,assuit branch, Al-Azhar University) — Principal investigator
First posted
Oct 14, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Apr 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

AL-Hassan Hatem Mohamed
Contact
alhasanhatem49@gmail.com
+201029086038
Esmail Kamel Hewy
Contact
esmailhewy1459.el@azhar.edu.eg
+201003856173
Mohamed Ahmed Salim, Professor
study director · Al-Azhar University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Al-Azhar University →

Start the discussion